Rothschild & Co Redburn initiated coverage of MoonLake Immunotherapeutics (MLTX) with a Neutral rating and $65 price target Published first on ...

When building your watch list, look for stocks with an 80 or higher RS Rating. MoonLake Immunotherap MLTX is one stock that ...

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “The new $500 million facility further strengthens our financial position.

ZUG, Switzerland, May 12, 2025 – MoonLake Immunotherapeutics (MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for ...

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion. While MoonLake turned down the initial offer ...

MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials, yet faced a significant stock drop due to institutional sell-offs. Despite ...

MoonLake Immunotherapeutics, a clinical-stage biotechnology firm, is set to hold a virtual Capital Markets Day on April 29, 2025, aimed at investors and analysts.

MoonLake Immunotherapeutics shares are currently trading up about 18.7% on the day. The chart below shows the one year performance of MLTX shares, versus its 200 day moving average: ...

MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26. The stock has a market cap of $2.49 billion, a price-to-earnings ratio of -30.18 and a beta of 1.31.

MoonLake Immunotherapeutics (NASDAQ:MLTX) is investing in this growth opportunity and large clinical development programs while preparing for regulatory filings and other pre-commercial activities.

MoonLake Immunotherapeutics (NASDAQ:MLTX) is investing in this growth opportunity and large clinical development programs while preparing for regulatory filings and other pre-commercial activities.